Search

Search Constraints

You searched for: Author/Creator Pfeifer, Andrea

Search Results

1. [IC‐01–05]: FIRST‐IN‐HUMAN PET STUDIES WITH THE NEXT GENERATION TAU AGENT 18‐F PI‐2620 IN ALZHEIMER's DISEASE, PROGRESSIVE SUPRANUCLEAR PALSY, AND CONTROLS. (1st July 2017)

2. [IC‐P‐192]: PRECLINICAL CHARACTERIZATION OF PI‐2620, A NOVEL TAU PET TRACER FOR DETECTION OF TAU IN AD AND OTHER TAUOPATHIES. (1st July 2017)

3. [P2–381]: PRECLINICAL CHARACTERIZATION OF PI‐2620, A NOVEL TAU PET TRACER FOR DETECTION OF TAU IN AD AND OTHER TAUOPATHIES. (1st July 2017)

4. [P3–067]: DEVELOPMENT OF HIGHLY SENSITIVE MSD ASSAYS FOR THE DETECTION OF ANTI‐AMYLOID β MONOMER‐ AND OLIGOMER‐SPECIFIC ANTIBODIES IN HUMAN SERUM. (1st July 2017)

5. [P4–099]: CHANGES IN TAU PROTEIN LANDSCAPE DURING ALZHEIMER's DISEASE PROGRESSION. (1st July 2017)

6. ACI‐24 in adults with Down syndrome: Results of a phase 1b, randomized, placebo‐controlled study. (31st December 2021)

7. ACI‐24 in adults with Down syndrome: Results of a phase 1b, randomized, placebo‐controlled study. (31st December 2021)

8. ACI‐24 vaccine in adults with Down syndrome: Human: Putative therapeutic results for Alzheimer's and related dementias. (7th December 2020)

9. Biomarker‐based development for optimized ACI‐24, a novel candidate vaccine for the treatment and prevention of Alzheimer's disease. (20th December 2022)

10. Calpain-mediated tau fragmentation is altered in Alzheimer's disease progression. Issue 1 (December 2018)